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Summary A large number of cells containg subunit a of blood coagulation Factor XIII (FXIII) was detected
by immunoperoxidase staining in lymph nodes with Hodgkin's disease. These relatively large, multipolar,
mononuclear cells were often found in the immediate vicinity of malignant Hodgkin's cells. Intensive
characterization of these cells carried out by immunofluorescent and enzymecytochemical techniques in
double- and triple-labelling systems on the same sections clearly demonstrated that they represent tumour-
associated macrophages (TAMs). FXIII containing-cells showed a-naphtyl acetate esterase (ANAE) positivity,
and were labelled by monoclonal anti-Leu M3 antibody, a monocyte/macrophage marker, but not at all or
only very weakly by anti-HLA-DR. Neither alkaline phosphatase (ALP) nor adenosine triphosphatase
(ATPase) activity could be detected in these cells and surprisingly, they were consistently negative for acid
phosphatase (AcP) as well. The presence of FXIII subunit a in tumour-associated macrophages suggests that
this cell type might have an important role in the stabilization of fibrin deposits around tumour cells.
Fibrin deposition is a rather frequent finding in
spontaneously-arising as well as transplantable human and
animal tumours and has been implicated in various aspects
of tumour growth and metastasis (Rickles & Edwards, 1983;
Dvorak et al., 1983). Though most or perhaps all malignant
cells possess procoagulant activities (O'Meara, 1958; Gordon
et al., 1975; 1979; Gordon & Cross, 1981; Semeraro &
Donati, 1981) that can activate the coagulation cascade, it is
becoming increasingly evident that tumour-associated macro-
phages (TAMs) are also involved in intra-tumoral fibrin
formation (Edwards et al., 1981; Evans, 1982; Lorenzet et
al., 1983; Key, 1983).
Macrophages or, in view of their heterogeneity (Hopper et
al., 1979; Poulter et al., 1983), certain of their subsets could
contribute to extravascular clotting by two mechanisms. (i)
By expressing tissue factor activity they can initiate the
extrinsic coagulation pathway (Rickles & Edwards, 1983;
Dvorak et al., 1983; Lorenzet et al., 1983). (ii) They contain
a number of clotting factors which, if secreted or released
from damaged cells into the interstitial space, provide all the
components necessary for extrinsic thrombin formation. The
production of vitamin K-dependent clotting factors (Factor
II, VII, IX, X) and Factor V by macrophages has been well
established (Osterud et al., 1980; Lindahl et al., 1982; van
Dam-Mieras et al., 1985; Chapman et al., 1985). Most
recently the presence of subunit a of Factor XIII (FXIII),
the enzymatically-active constituent of fibrin stabilizing fac-
tor has also been demonstrated in human peripheral blood
monocytes (Muszbek et al., 1985) and peritoneal macro-
phages (Adany et al., 1985) in our laboratory. Independ-
ently, these results have been confirmed by Henriksson et al.
(1985). FXIII delivered by macrophages into the tumour
stroma might have an important role in the stabilization of
fibrin formed extravascularly and in its activated form as a
transglutaminase it might exert other biological functions as
well. Thus, it was interesting to see if TAMs or certain
subsets of them contain FXIII.
The presence of fibrin deposits in lymph nodes with
Hodgkin's disease is a general observation (Harris et al.,
(1982; Dvorak et al., 1983) and in these lymph nodes
macrophage-like cells prevail over all other cell types in areas
rich in fibrillar intercellular substance (Stiller & Katenkamp,
1978; Hansmann & Kaiserling, 1981). Here we show that a
distinct cell population in lymph nodes with Hodgkin's
disease contains subunit a of FXIII. The macrophage nature
of these cells is clearly demonstrated and by using double-
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and triple-labelling techniques the FXIII containing subset of
TAMs is extensively characterized. Triple labelling systems
provide an excellent opportunity to carry out an exact
characterization of a cell population, because the direct
demonstration of two different antigens in combination with
enzyme-cytochemical reactions in the same section yields a
precise representation of the coincidence of three different
characteristics.
Materials and methods
Lymph node biopsies were obtained from 12 patients with
Hodgkin's disease of nodular sclerosing type. Sections from
non-neoplastic, reactive lymph nodes served as controls. All
specimens were divided into two parts at the time of surgical
biopsy. One part was fixed in 3.5% paraformaldehyde
fixative (4h, room temperature) then vacuum embedded in
paraffin and sectioned into 6pim slides, while the other part
was snap-frozen and cut in a cryostat. Six m frozen sections
were air-dried, wrapped in foil and stored at -20°C.
Immunoperoxidase staining
Formaldehyde-fixed paraffin embedded sections were de-
waxed and rehydrated. Endogenous peroxidase activity was
blocked by I % H202 in absolute methanol for 30 min at
room temperature. Sections were digested with 0.1 % trypsin,
in TRIS-buffered saline (pH 7.6) containing 0.1% calcium
chloride at 37DC for 20min. Non-specific IgG binding was
prevented by preincubation with 20% normal goat serum for
15 min. Sections were covered for 2 h, at room temperature
with rabbit antiserum against FXIII subunit a (Behringwerke
AG, Marburg, West Germany) diluted 1:25 with 20%
normal goat serum. The monospecifity of this antiserum was
verified by immunoblotting on whole human plasma as well
as on human platelet and monocyte homogenate (Muszbek
et al., 1985). Antigen-antibody reaction was detected by
biotinylated anti-rabbit IgG and avidin-biotinylated per-
oxidase complex (Vectastain ABC kit) (Vector Laboratories,
Burlingame, CA). The specific peroxidase activity was
visualized by 0.05% 3,3'-diaminobenzidine tetrahydro-
chloride (DAB) (Sigma Co., St. Louis, MO), 0.01% H202
in 0.1 mol 1- 1 TRIS HCI buffer, pH 7.2. Counterstaining
was with Mayer's haematoxylin before dehydration in
graded alcohol and mounting with Canada balsam. On
control slides normal rabbit serum at the same dilution was
used instead of anti FXIII subunit a antiserum. PBS, pH 7.3,
was used for antibody dilution and in washing procedures.
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Immunofluorescent and enzyme-histochemical techniques
Frozen sections were used for the double immunolabelling
techniques combined with the cytochemical localization of
several enzymes on the same slide (combined triple labelling
systems). Immediately before immunoreactions cryostat sec-
tions were unwrapped and fixed in acetone at +4°C, for
10 min. After washing in PBS, slides were incubated with
1:200 dilution of antiserum against FXIII subunit a for 2 h
at room temperature. As the secondary antiserum, a 1:40
dilution of swine anti-rabbit IgG fluoresceinated (Dakopatts
a/s, Glostrup, Denmark), was used (30 min incubation). In the
next stage this reaction was combined either with the
detection of HLA-DR antigen or with the visualization of
Leu M3, a monocyte/macrophage surface marker. Sections
were incubated with 1:5 dilution of biotinylated mouse anti-
human HLA-DR monoclonal antibody (Becton-Dickinson,
Sunnyvale, CA) or with the same dilution of mouse anti-
human Leu M3 monoclonal antibody conjugated with phyco-
erythrin (Becton-Dickinson, Sunnyvale, CA) for 30 min, at
room temperature. The specific binding of biotinylated anti-
HLA-DR antibody was detected by 1:40 dilution of
streptavidin-Texas red (Amersham, UK). In the case of
negative controls non-immune rabbit serum and control
mouse IgG from tumour-bearing BALB/c mice conjugated
with phycoerythrin or FITC (Becton Dickinson, Sunnyvale,
CA) were substituted for the first antibodies.
Following double immunofluorescent staining, sections
were mounted in 50% glycerol in PBS and examined under
an Opton ultraviolet microscope equipped with an
epifluorescence condensor containing selective filters for
FITC and Texas red/phycoerythrin. After photographs had
been taken, cover-slips were removed, sections were washed
thoroughly in distilled water.
As a third step, one of the following enzymes was
detected: oc-napthyl acetate esterase (ANAE) (Mueller et al.,
1975), acid phosphatase (AcP) (Poulter et al., 1983), aden-
osine triphosphatase (ATPase) (Poulter et al., 1983) and
alkaline phosphatase (ALP) (Mason & Woolston, 1982).
In the case of negative control slides in the enzymecyto-
chemical reactions either the substrate was omitted from the
incubation medium, or before development of an enzyme
reaction the appropriate enzyme activity was blocked accord-
ing to the recommendation of Poulter et al. (1983). Finally,
sections were remounted in 50% glycerol in PBS and the
fields of which photographs had been previously taken were
identified in normal light microscope and rephotographed.
Using the above-mentioned immuno- and enzyme-histo-
chemical reactions all possible combinations of triple label-
ling were performed on every biopsy specimen.
Results
Immunoperoxidase staining on paraformaldehyde-fixed,
paraffin embedded sections was used to verify the presence
and determine the distribution of FXIII subunit a containing
cells in lymph nodes with Hodgkin's disease of nodular
sclerosing type. As demonstrated in Figures la, 4b, 5a and
6a practically the whole area of lymph node was infiltrated
by cells showing intensive staining for FXIII. These cells
were often found in the immediate vicinity of malignant
Hodgkin's cells suggesting an intimate relationship between
the two cell types (Figure lb).
FXIII containing-cells in lymph nodes with Hodgkin's
disease possess a macrophage-like appearance, they are relat-
ively large, multipolar, mononuclear cells with numerous
vacuoles in the cytoplasm. Their detailed characterization
was performed by triple labelling (double immuno-
fluorescent + enzyme-cytochemical) techniques. Staining for
FXIII and the monocyte/macrophage marker Leu M3
(Dimitriu-Bona et al., 1983) showed an identical distribution
pattern in each case (Figure 3a, b). This fact together with
their definite ANAE positivity (Figure 4b, c) clearly iden-
tifies FXIII containing-cells as members of the macrophage
family. These cells were predominantly negative for HLA-
DR though occasionally very weak positive staining could
also be detected (Figures 2, 4a, b). ALP (Figure 5a, b) and
ATPase activities (not shown) could not be detected in
FXIII containing cells and surprisingly, they were consist-
ently negative for AcP (Figure 6a, b), as well. The presence
of HLA-DR or AcP positive but FXIII negative cells with
macrophage-like morphological features clearly indicates that
FXIII is expressed only in a certain subset of TAMs.
In contrast to lymph nodes with Hodgkin's disease, in
reactive lymph nodes, FXIII containing cells were localized
almost exclusively in perivascular connective tissue and in
subcapsular or medullary sinuses. Macrophages in follicles of
reactive lymph nodes identified by strong ANAE reaction
were consistently negative for FXIII subunit a and only a
few positive cells could be detected in the interfollicular
areas (not shown). A detailed characterization of FXIII
containing-cells in reactive lymph nodes is published
elsewhere (Nemes et al., 1986).
Discussion
Plasma FXIII, like most other clotting factors circulates as a
zymogen. It is a tetrameric protein consisting of two types of
subunits (a2b2). The potential enzymatic site is located on
subunit a which can assume an active configuration only
following proteolytic cleavage by thrombin and Ca2 + in-
duced dissociation from the inhibitory b subunit (see
Muszbek & Laki, 1984 for review). It has been known for a
long time that subunit a but not b also exists as an
intracellular protein in platelets (Buluk, 1955), mega-
karyocytes (Kiesselbach & Wagner, 1972) and placenta
(Bohn & Schwick, 1971). As mentioned earlier the existence
of subunit a in monocytes has also been verified (Muszbek et
al., 1985) and these cells retain their FXIII content following
differentiation into peritoneal macrophages (Ad'any et al.,
1985). Furthermore, it was shown that FXIII containing cells
in the placenta are also of macrophage origin (Adany &
Muszbek, submitted for publication).
In this study a cell type expressing FXIII subunit a was
detected in lymph nodes with Hodgkin's disease. The morpho-
logical appearance of FXIII containing cells indicated that
they belong to TAMs, thus combinations of immuno- and
enzyme-histochemical reactions - generally used for identifi-
cation and/or phenotyping of macrophages - were applied to
characterize them. Their macrophage nature was clearly
demonstrated by Leu M3 and ANAE positivity. At the same
time negative reactions were found for HLA-DR, AcP, ALP
and ATPase.
The above results strongly suggest that this FXIII
containing-TAM cell type is not identical with any of the
macrophage cell types characterized earlier in normal human
lymph node. This conclusion is clearly supported by the
following data: (i) FXIII containing-macrophages are not
identical with interdigitating reticular cells and dentritic cells
of lymph node because the latters are strongly positive for
HLA-DR and ATPase (Janossy et al., 1980; Stein et al.,
1980; Poulter et al., 1983). (ii) They differ from sinus
histiocytes of normal lymph node and from inflammatory
macrophages, as well as by the absence of AcP activity
(Poulter et al., 1983). (iii) Being ALP negative they may not
be interpreted as fibroblastic reticulum cells (Chilosi et al.,
1981). On the other hand, FXIII containing-cells in lymph
nodes with Hodgkin's disease are not even identical with
other FXIII containing-cells of normal lymph nodes which
occur in the connective tissue of capsule and in the sinus
(Nemes et al., 1986). HLA-DR positivity of connective tissue
histiocytes as well as the intensive AcP reaction of sinus
macrophages clearly distinguish the latter cell types from
FXIII containing-TAMs.
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Figure 1 Immunoperoxidase staining for FXIII subunit a combined with haematoxylin-chromotrope counterstaining on a section
of paraformaldehyde-fixed, paraffin embedded lymph node with Hodgkin's disease, nodular sclerosis type. FXIII subunit a-
containing cells (in brown colour) invaded practically the whole area of lymph node (a) and were frequently found in the
immediate vicinity of malignant Hodgkin's cells (b). Bar= 25 gm (a) and 10pm (b).
Figure 2 Double immunofluorescent labelling for FXIII subunit a and HLA-DR on a cryostat section of lymph node with
Hodgkin's disease. In a double exposure photograph green FXIII containing cells are easily distinguishable from Texas red
labelled HLA-DR positive ones. Bar =10lOm.
Figure 3 In lymph node with Hodgkin's disease identical cells were labelled with immunofluorescent staining for FXIII subunit a
(a) and for the monocyte/macrophage surface antigen Leu M3 (b). Bar= 10pm.
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Figure 4 Triple labelling for HLA-DR (a), FXIII subunit a (b)
and ANAE (c) on the same area of lymph node with Hodgkin's
disease. FXIII containing cells are ANAE positive (see arrows),
but HLA-DR negative. Bar= 25 im.
Different types of macrophages originate from a common
bone marrow precursor (van Furth, 1981) but owing to an
intricate differentiation program associated with the ex-
pression and disappearance of various gene products
(Dimitriu-Bona et al., 1983) they show an extreme pheno-
typic and functional diversity. In consideration of this fact
we believe that FXIII containing-TAMs are a subset of
macrophages differentiated from blood monocytes for special
function(s) related to malignant cell proliferation. Indepen-
dently from FXIII containing-macrophages some AcP
positive macrophage-like cells were also detected. This find-
ing together with the presence of HLA-DR positive, but
FXIII negn-itive cclls in lymph nodes with Hodgkin's diseaise
support the possibility that TAMs are to be considered as an
inhomogeneous cell population.
Extravascular fibrin deposition occurs in the stroma and
at host-tumour interface in most or perhaps all malignant
neoplasms (Dvorak et al., 1983). The pathological signi-
ficance and the origin of fibrin deposits has not been
sufficiently explored. Most of the available clinical and
experimental data, however, tend to support* the view that
the activation of clotting system is beneficial for both
tumour progression and metastasis formation. Mostly on the
basis of theoretical considerations the following hypotheses
have been proposed for the pathogenic role of fibrin formed
between and around tumour cells: (1) it might have a barrier
function and interferes with the host's immune response, (2)
it could stimulate tumour angiogenesis, (3) it may have a
role in the implantation of circulating tumour cells at
metastatic sites (Dvorak et al., 1983). An important role for
FXIII - fibrin stabilizing factor - in any of the above
mechanisms seems rather obvious. By forming fibrinolysis-
resistant fibrin meshwork and crosslinking fibnrllar inter-
cellular matrix components, FXIII might support the barrier
function or might even be essential to it. The process of
angiogenesis and fibroplasia during tumour growth and
wound healing has been compared (Dvorak et al., 1983) and
it is well known that wound healing is highly impaired in
FXIII deficient patients (Duckert, 1972). A possible direct
effect of FXIII on cell proliferation, as observed in the case
of fibroblasts (Beck et al., 1961), might also have some
implications for tumour growth. A further possibility con-
cerns the transglutaminase nature of activated FXIII. As a
transglutaminase it can attach host proteins covalently to the
membrane of tumour cells and mask their putative 'non-self'
character resulting in increased immune resistance. The latter
idea is supported by data showing that attachment of
fibrinogen to the membrane of YPC-1 plasmocytoma cells
by tissue transglutaminase results in an inhibition of cell
mediated cytotoxic response (Hunyadi et al., 1981).
In tumours FXIII could get into the interstitial space from
two possible sources. It may leak from blood vessels together
with other plasma proteins due to enhanced microvascular
permeability or it may originate from the TAM subgroup
described here by active secretion and/or release following
cell destruction. However, this question has not been ad-
dressed experimentally. Clearly, further investigations are to
be carried out to test the above hypotheses and establish the
role of FXIII as well as FXIII containing-TAMs in the
progression of malignant tumours.
These studies were conducted in part pursuant to a contract with the
National Foundation for Cancer Research, Bethesda, Maryland,
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Figure 5 Immunofluorescent staining for FXIII subunit a (a) combined with the detection of alkaline phosphatase (b) on the
same section of lymph node with Hodgkin's disease. As alkaline phosphatase activity was revealed with naphtol AS-MX plus Fast
Red TR the end product of the reaction appeared in red colour not only in normal light but on the FITC channel of the
fluorescence microscope, as well. On the photograph it is superimposed on FITC labelled immunreaction for FXIII subunit a.
FXIII containing macrophages are negative for alkaline phosphatase. Bar=25pm.
Figure 6 In lymph node with Hodgkin's disease immunofluorescent staining for FXIII subunit a (a) and acid phosphatase
activity detection (b) visualize two distinct cell populations. Bar=25pm.
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